Skip to main content

Adacel FDA Approval History

FDA Approved: Yes (First approved June 10, 2005)
Brand name: Adacel
Generic name: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)
Company: Aventis Pasteur Limited
Treatment for: Tetanus Prophylaxis, Diphtheria Prophylaxis, Pertussis Prophylaxis

Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) is indicated for active booster immunization for the prevention of tetanus, diphtheria and pertussis.

Development timeline for Adacel

DateArticle
Jan 17, 2023Approval FDA Approves Adacel for Immunization During Pregnancy to Help Protect Young Infants Against Pertussis
Jan 14, 2019Approval FDA Approves Expanded Use of Adacel (Tdap) Vaccine for Repeat Vaccination
Apr  1, 2014Approval Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel Tdap Vaccine to Include Persons 10 Years of Age
Jun 13, 2005Approval U.S. FDA Licenses sanofi pasteur’s Adacel Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
Mar 15, 2005FDA Advisory Panel Recommends Licensure of Sanofi Pasteur's Adacel Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
Aug 11, 2004Aventis Submits Application for FDA Licensure of Adacel Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults

See also

Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer